Adamed Pharma has signed a preliminary agreement with Sanofi regarding the acquisition of a manufacturing facility in Riells i Viabrea, Spain. This marks another step in the Polish company’s international expansion. The transaction aims to increase production capacity, diversify manufacturing locations, and strengthen supply chain resilience and drug security in Europe.
Transaction Schedule and Conditions
The formal closing of the transaction is planned for the second quarter of 2026. Until then, production will continue without disruption, and the acquisition process will be implemented gradually.
Upon completion of the transition period, Adamed will take over the operational management of the plant. The company has pledged to maintain current employment levels and existing working conditions.
“We want to build upon the foundation that is already there: the people, their knowledge, and their experience. This is a robust facility with a bright future ahead. It is a long-term project in which we intend to invest so that it plays a significant role in the coming years,” emphasizes Małgorzata Adamkiewicz, MD, PhD, Chairwoman of the Supervisory Board and Co-owner of Adamed Pharma.
The Riells Facility – Further Development
The facility in Riells has been operating for over 50 years and specializes in the production of tablets and capsules. It employs over 200 people and manufactures approximately 75 million packs of medicine annually. The output is distributed to 77 countries worldwide, primarily for export.
“The Riells site plays an important role in delivering medicines to patients globally. We are committed to the long-term stability and development of our manufacturing sites. We are convinced that under Adamed’s leadership, the facility will maintain the highest standards of quality and safety,” said Marzia Bove, Head of Manufacturing & Supply Chain (General Medicines Sanofi).
The plant will become one of the key points in Adamed’s international production network, focusing on high-volume drug manufacturing primarily for European markets. The company plans to invest in modernizing production, infrastructure, and logistics, as well as adapting the facility to current and new products.
“In large, international manufacturing companies, it is standard practice to reduce reliance on a single manufacturing site. Such diversification gives us greater flexibility and operational reliability. Spain is a strategic location for us, offering a gateway to Latin American markets where we intend to strengthen our presence,” emphasizes Paweł Roszczyk, CEO of Adamed Pharma.
Sanofi’s Decision
The decision to sell the Riells facility stems from the corporation’s strategy to become a global leader in immunology and its efforts to adapt its global industrial network to the future needs of the drugs currently under development.
Under the agreement, in addition to introducing Adamed’s products to the lines, Adamed will continue to manufacture Sanofi medicines at the Riells facility for several years. This is intended to ensure full continuity of supply and no changes for patients. Product ownership and commercial distribution will remain with Sanofi.
Spain and Poland at the Center of Adamed’s Growth
Adamed has been present in Spain since 2009 through its subsidiary, Adamed Laboratorios. It is currently the company’s second-largest market in Europe in terms of revenue, characterized by a stable growth outlook.
Simultaneously, Adamed is investing in Poland, where it operates two production plants—in Pabianice and Ksawerów. The company is expanding its Logistics and Production Center in Pabianice and plans to allocate approximately PLN 300 million by 2030 for projects including the construction of an inhaled drugs factory. Over the last 5 years, Adamed has increased drug production by 75%—from 2 billion to 3.5 billion tablets annually. With the acquisition of the Riells facility, the company plans to double its production volume to 7 billion tablets annually by 2029.
International Strategy of the Polish Firm
The facility in Riells will be the second foreign factory in Adamed’s international production network. Since 2017, the company has owned a factory in Vietnam. Medicines from the Polish company reach patients in over 80 countries across 6 continents.
